Home / Market News / $SLN
benzinga Corporate Catalyst Impact 65/100 ● negative

HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20

Oct 21, 2026, 11:48 AM UTC · Primary ticker $SLN

HC Wainwright & Co. downgraded Silence Therapeutics from Buy to Neutral and significantly reduced its price target from $75 to $20. This analyst action indicates a revised outlook on the company's prospects, likely due to new information or a re-evaluation of existing data, which could lead to downward pressure on the stock.

HC Wainwright & Co. downgraded Silence Therapeutics (SLN) from a 'Buy' to a 'Neutral' rating and drastically cut its price target from $75 to $20. This significant revision by a covering analyst suggests a material change in their investment thesis, likely stemming from concerns about the company's pipeline, clinical trial outcomes, market potential, or competitive landscape. This news is immediately negative for SLN, as it signals a loss of confidence from a key analyst and could trigger selling pressure from institutional investors who follow such ratings. In the short term, SLN's stock price is likely to experience downward pressure. Long-term implications depend on whether the analyst's concerns are validated by future company performance or if the market views this as an overreaction. For traders, the key risk is further downside if other analysts follow suit or if the company fails to address the underlying concerns that led to the downgrade.

$SLN negative analyst downgrade and price target cut
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.